Well, we've got a stable cell line for production:
Patrys Establishes Stable Cell Line for Production of PAT-DX1
https://www.patrys.com/site/market-announcements/2021/663%20Patrys%20Successfully%20Establishes%20PAT-DX1%20Stable%20Cell%20Line_10%20February%202021.pdf
Melbourne, Australia; 10 February 2021: Patrys Limited (ASX: PAB, “Patrys” or the Company), a therapeutic antibody development company, is pleased to announce it has selected an optimised stable cell line for its lead asset PAT-DX1. This important step allows the company to establish largescale production of PAT-DX1 deoxymab for final preclinical studies, first-in-man studies, and partnering activities.
